# EDGAR Filing Document

**Accession Number:** 0001640266
**File Stem:** 0001104659-23-024436
**Filing Date:** 2023-2
**Character Count:** 45355
**Document Hash:** ac8802274d255600aa48ccb459ffcd56
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-024436.hdr.sgml**: 20230223

**ACCESSION NUMBER**: 0001104659-23-024436

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230222

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230223

**DATE AS OF CHANGE**: 20230223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Voyager Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001640266
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37625
- **FILM NUMBER:** 23655766

**BUSINESS ADDRESS:**
- **STREET 1:** 64 SIDNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 857-259-5340

**MAIL ADDRESS:**
- **STREET 1:** 64 SIDNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 8-K**

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **February 22, 2023**

**Voyager Therapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37625** | **46-3003182** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **64 Sidney Street**<br> **Cambridge, Massachusetts** | **02139** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code **(857) 259-5340**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which<br> registered |
| Common Stock, $0.001 par value | VYGR | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On February 22, 2023 (the "Agreement Date"), Voyager Therapeutics, Inc. (the "Company") and Robert W. Hesslein entered into a Transition, Separation and Release of Claims Agreement (the "Separation Agreement"), pursuant to which Mr. Hesslein resigned from his position of Senior Vice President and General Counsel and from any and all other positions he holds as an officer or employee of the Company or an officer, employee or director of any of its subsidiaries, effective on April 28, 2023, or such earlier date as may be mutually agreed upon in writing by the Company and Mr. Hesslein (as applicable, such date, the "Separation Date").

During the period between the Agreement Date and the Separation Date (the "Transition Period"), Mr. Hesslein has agreed to continue to serve as Senior Vice President and General Counsel and to assist with the transition of his duties and responsibilities. Mr. Hesslein will continue to receive his base salary, in effect as of the Agreement Date, and during the Transition Period will remain eligible to participate in Company benefit plans and eligible for vacation time.

Pursuant to the terms of the Separation Agreement, the Company has agreed, consistent with Mr. Hesslein's existing employment agreement, to (1) make salary continuation payments to Mr. Hesslein, in accordance with the Company's regular payroll practices, for a period of twelve months following the effectiveness of his execution of an additional release of claims (the "Separation Pay Period") based on his annualized base salary in effect on the Separation Date; (2) provide to Mr. Hesslein a prorated annual bonus payment for 2023 based on his target bonus percentage and his time of employment in 2023 through the Separation Date, paid in equal installments based on the Company's regular payroll practices over the Separation Pay Period; and (3) subject to Mr. Hesslein's eligibility for continued coverage under COBRA, pay on Mr. Hesslein's behalf the portion of the premium for group health insurance coverage that the Company pays to active and similarly situated employees receiving the same type of coverage, for a period of twelve months following the Separation Date or, if earlier, the end of the calendar month when Mr. Hesslein becomes eligible to receive group health insurance coverage under another employer's benefit plan.

The Separation Agreement also provides for, among other things, a release of claims by Mr. Hesslein in favor of the Company and its affiliates; continuing confidentiality and non-solicitation obligations applicable to Mr. Hesslein under his existing confidentiality, non-solicitation and invention assignment agreement with the Company (the "Restrictive Covenants Agreement"); non-disparagement and cooperation obligations applicable to Mr. Hesslein; and non-disparagement obligations applicable to the Company. In connection with the parties' execution of the Separation Agreement, Mr. Hesslein's employment agreement with the Company was terminated as of the Agreement Date.

In accordance with the Separation Agreement, the Company and Mr. Hesslein also expect to enter into a consulting agreement (the "Consulting Agreement") upon the Separation Date pursuant to which Mr. Hesslein is to assist the Company with the transition of his responsibilities following his departure. In connection with the Consulting Agreement, Mr. Hesslein is to be available to provide specified consulting services from time to time and as requested by the Company. The Company has agreed to pay Mr. Hesslein for the services he renders to the Company at an hourly consulting rate, in addition to any pre-approved expenses and pass-through costs relating to the consulting services.

Under the Separation Agreement, the Consulting Agreement shall become effective upon the Separation Date and shall remain in effect until September 30, 2023, unless it is, in accordance with its terms, extended by mutual written consent of the parties; terminated by the mutual written consent of the parties; terminated by either party upon written notice to its counterparty upon a material breach of the Consulting Agreement or the Separation Agreement by its counterparty; terminated by the Company upon written notice to Mr. Hesslein upon a material breach of the Restrictive Covenants Agreement by Mr. Hesslein; terminated by either party without cause upon specified written notice of such termination; or terminated automatically upon the occurrence of other specified conditions (the effective period of the Consulting Agreement, the "Consulting Period").

In consideration for Mr. Hesslein entering into the Separation Agreement and the Consulting Agreement, (1) each time-based unvested restricted stock unit award previously granted by the Company to Mr. Hesslein shall continue to vest and become free from forfeiture during the Consulting Period in accordance with the applicable restricted stock unit agreement and equity plan, as if Mr. Hesslein had remained employed during such period, and (2) each time-based unvested stock option previously granted by the Company to him shall continue to vest and become exercisable during the Consulting Period in accordance with the applicable option agreement and equity plan as if Mr. Hesslein had remained employed during such period, subject to in each case (i) Mr. Hesslein continuing to provide services under the Consulting Agreement, (ii) Mr. Hesslein executing and delivering an additional release of claims and the continuation thereof without revocation, and (iii) Mr. Hesslein complying with the terms of the Separation Agreement and Restrictive Covenants Agreement. Pursuant to the terms of the Separation Agreement, the Company has also agreed to extend the period during which Mr. Hesslein may exercise any outstanding and vested stock options held by him to six months following the expiration or termination of the Consulting Period. If the Consulting Agreement is terminated by the Company without cause, the vesting of each restricted stock unit award and stock option granted by the Company to Mr. Hesslein that would have vested had Mr. Hesslein continued to provide services through the expiration of the Consulting Period pursuant to the Consulting Agreement shall immediately accelerate and shall become exercisable in accordance with the applicable award agreement.

The foregoing summaries of the Separation Agreement and the Consulting Agreement are qualified in their entirety by reference to the complete text of each such agreement. A copy of the Separation Agreement is filed as an exhibit to this Current Report on Form 8-K and is incorporated herein by reference. The Company expects to file a copy of the Consulting Agreement as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2023.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| [10.1](tm237527d1_ex10-1.htm) | [Transition, Separation and Release of Claims Agreement, by and between the Company and Robert W. Hesslein, dated February 22, 2023.](tm237527d1_ex10-1.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **VOYAGER THERAPEUTICS, INC.** | **VOYAGER THERAPEUTICS, INC.** |
| Date: February 23, 2023 | By: | /s/ Alfred Sandrock, M.D., Ph.D. |
|  |  | Alfred Sandrock, M.D., Ph.D.<br> Chief Executive Officer, President, and Director |
|  |  | *(President and Chief Executive Officer)* |

---

## Exhibit 10.1

**Exhibit 10.1**

***Execution Version***

**<u>TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENT</u>**

This Transition, Separation and Release of Claims Agreement (this "<u>Agreement</u>") is made as of the Agreement Effective Date (as defined below) by and between Voyager Therapeutics, Inc. (the "<u>Company</u>") and Robert W. Hesslein ("<u>Executive</u>") (together, the "<u>Parties</u>").

**WHEREAS**, the Company and Executive are parties to the Employment Agreement dated as of January 15, 2019 (the "<u>Employment Agreement</u>"), under which Executive currently serves as the Company's Senior Vice President and General Counsel;

**WHEREAS**, the Parties have mutually agreed to establish terms for Executive's separation from employment with the Company; and

**WHEREAS**, the Parties agree that the payments, benefits and rights set forth in this Agreement shall be the exclusive payments, benefits and rights due Executive in connection with his separation from employment with the Company.

**NOW, THEREFORE**, in consideration of the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1.  **<u>Separation Date; Resignation from Position(s); Transition Period</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Executive and the Company have mutually agreed that Executive's effective date of separation from
employment with the Company will be (i) April 28, 2023, or (ii) such earlier date as may be mutually agreed upon in writing
by the Company and Executive (as applicable, the " <u>Separation Date</u> "). Executive hereby resigns, as of the Separation
Date, from his position as Senior Vice President and General Counsel of the Company, and from any and all other positions he holds as
an officer or employee of the Company or as an officer, employee or director of any subsidiary of the Company, and further agrees to execute
and deliver any additional documents reasonably necessary to effectuate such resignations, as requested by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) As of the Agreement Effective Date, the Employment Agreement will terminate and be of no further force
or effect; provided, however, that Executive's Confidentiality, Non-Solicitation and Invention Assignment Agreement dated January 15,
2019 and referenced in the Employment Agreement (a copy of which is attached hereto as Attachment A, and hereinafter, the " <u>Restrictive Covenants Agreement</u> ") shall remain in full force and effect both during the Transition Period (as defined below) and thereafter.
Notwithstanding the foregoing, and for the avoidance of doubt, the Company retains the right to unilaterally terminate Executive's
employment prior to the Separation Date for Cause (as defined in the Employment Agreement).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The period between the Agreement Effective Date and the Separation Date will be a transition period
 (the " <u>Transition Period</u> "). During the Transition Period, Executive will use his best efforts to professionally,
 timely, and cooperatively perform his duties, including, without limitation, assisting with the transition of his duties and
 responsibilities to other personnel as requested by the Company. During the Transition Period, Executive will continue to receive
 his current base salary, to participate in the Company's benefit plans (pursuant to the terms and conditions of such plans),
 and to be eligible for vacation time in accordance with Company policy (including Executive's taking previously scheduled vacation days from March 18, 2023 through and including March 30, 2023).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) In connection with Executive's separation from employment with the Company, Executive shall be paid,
in accordance with applicable law and the Company's regular payroll practices, all unpaid base salary earned through his last day
of employment, including any amounts for accrued unused vacation time to which Executive is entitled through such date in accordance with
Company policy, and reimbursement of any properly incurred unreimbursed business expenses incurred through such date (together, the " <u>Accrued Obligations</u> "). As of Executive's last day of employment, all salary payments from the Company will cease and any benefits
Executive had as of such date under Company-provided benefit plans, programs, or practices will terminate, except as required by federal
or state law or as otherwise specifically set forth in this Agreement. For the avoidance of doubt, Executive may, if eligible and at his
own cost, elect to continue receiving group medical insurance pursuant to applicable "COBRA" law (COBRA materials containing
details regarding such benefits will be provided to Executive under separate cover in accordance with applicable law).

2.  **<u>Severance Benefits</u>** – In consideration of Executive's entering into and
 abiding by the commitments and obligations set forth in this Agreement, and provided Executive (i) signs and returns this
 Agreement at or before 10:00 p.m. Eastern time on February 22, 2023, (ii) continues employment with the Company
 through the Separation Date in accordance with the terms hereof, (iii) signs and returns the Additional Release of Claims
 attached hereto as Attachment B (the " <u>Additional Release</u> ") no earlier than the Separation Date but by the later
 of the Separation Date and the twenty-second (22<sup>nd</sup>) day after the Receipt Date, and does not timely revoke such
 Additional Release, and (iv) complies with the terms of this Agreement, the Additional Release, and the Restrictive Covenants
 Agreement, the Company will provide Executive with the following severance benefits (the " <u>Severance Benefits</u> "):

(a) <u>Severance Pay</u> – Commencing on the Company's first regularly scheduled payroll date
that follows the Additional Release Effective Date (as defined below) (the " <u>Payment Commencement Date</u> "), and continuing
for twelve (12) months following the Payment Commencement Date (the " <u>Severance Payment Period</u> "), Executive will receive
during the Severance Payment Period severance pay in the form of salary continuation payments, less all applicable taxes and withholdings,
in accordance with the Company's regular payroll practices, resulting in an aggregate payment to Executive of an amount equal to
Executive's annualized base salary in effect on the Separation Date.

(b) <u>Group Health Insurance</u> – Should Executive be eligible for and timely elect to continue receiving group health and/or dental insurance coverage under the
law known as COBRA, the Company shall, commencing on the Separation Date, and continuing until the earlier of (x) the date that
is twelve (12) months following the Separation Date, and (y) the end of the calendar month in which Executive becomes eligible to
receive group health insurance coverage under another employer's benefit plan (the " <u>COBRA Contribution Period</u> "),
pay on Executive's behalf the portion of the premium for such coverage that it pays on behalf of active and similarly situated
employees receiving the same type of coverage. The balance of such premiums during the COBRA Contribution Period (if any and to the extent
not required to be paid by the Company pursuant to applicable law), and all premium costs after the COBRA Contribution Period, shall
be paid by Executive on a monthly basis during the elected period of health insurance coverage under COBRA for as long as, and to the
extent that, he remains eligible for and elects to remain enrolled in COBRA continuation coverage. Executive agrees that, should he become
eligible for group health insurance coverage from another employer prior to the date that is twelve (12) months following the Separation
Date, he will so inform the Company in writing within five (5) business days of becoming eligible for such coverage.

(c) <u>2023 Bonus</u> – The Company shall provide Executive with a
 prorated annual bonus payment for calendar year 2023 in the amount calculated by multiplying 100% of Executive's current
 target bonus (which current target bonus is equal to one hundred eighty thousand, three hundred and two dollars ($180,302.00)) by a
 fraction, the numerator of which is the number of days in 2023 up to the Separation Date and the denominator of which equals 365,
 less applicable taxes and withholdings (the " <u>2023 Bonus Payment</u> "). The 2023 Bonus Payment shall be divided by the
 number of regularly scheduled pay periods occurring during the Severance Pay Period, and the quotient of such division shall be
 paid, less all applicable taxes and withholdings, to Executive in accordance with the Company's regular payroll practices
 commencing on the Payment Commencement Date.

(d) <u>Outplacement Services</u> – The Company shall provide
 Executive with comprehensive career services through Keystone Partners for up to six (6) months. The use of these services must
 occur within the six-month period commencing after the expiration of the Revocation Period. Such services will be provided to
 Executive so long as Executive (i) is actively and diligently cooperating with Keystone Partners, (ii) is using diligent
 efforts to obtain other employment or to pursue other opportunities that may not involve employment, and (iii) has not yet accepted new employment. The cost of these outplacement
 services, up to a total of fifteen thousand dollars ($15,000), will be paid directly to Keystone Partners by the
 Company.

Other than the Accrued Obligations, the Severance Benefits, and the Consulting Agreement (as described in Section 3 below), Executive will not be eligible for, nor shall he have a right to receive, any payments, benefits or other consideration from the Company following the Separation Date.

For the avoidance of doubt, Executive acknowledges that he is not eligible for or entitled to receive any severance benefits pursuant to the Employment Agreement, and further acknowledges that he will not be eligible to receive the Severance Benefits or the Consulting Agreement (or any payments or benefits from the Company other than the Accrued Obligations) if he fails to timely enter into this Agreement and the Additional Release, or if he revokes the Additional Release, or if his employment is terminated by the Company for Cause or by him for any reason prior to the Separation Date, or if he fails to comply with his obligations under this Agreement or the Restrictive Covenants Agreement.

3.  **<u>Consulting Agreement</u>** – Provided that Executive continues employment through the
 Separation Date in accordance with the terms hereof and complies with all provisions of this Agreement and the Restrictive Covenants
 Agreement, the Company and Executive shall, upon the Separation Date, enter into a consulting agreement in the form attached to this
 Agreement as Attachment C (the " <u>Consulting Agreement</u> "). It is understood and agreed that, so long as
 (a) Executive enters into the Consulting Agreement on the Separation Date, (b) timely executes this Agreement and the
 Additional Release and does not revoke the Additional Release, and (c) complies at all times and in all material respects with
 his obligations under this Agreement and the Restrictive Covenants Agreement, during the period Executive is providing services
 under the Consulting Agreement (the " <u>Consulting Term</u> ") (i) all time-based unvested restricted stock unit
 awards granted by the Company to Executive in connection with his employment with the Company shall continue to vest and become free
 from forfeiture in accordance with the applicable award agreement(s) and equity plan(s) as if Executive had continued to
 remain employed during the Consulting Term; (ii) such restricted stock unit awards will cease vesting immediately upon
 expiration or termination of the Consulting Term for any reason in accordance with Section 2 of the Consulting Agreement;
 (iii) all time-based unvested stock option awards granted by the Company to Executive in connection with his employment with
 the Company (the " <u>Options</u> ") shall continue to vest and become exercisable in accordance with the applicable
 option agreement(s) and equity plan(s) as if Executive had continued to remain employed during the Consulting Term;
 (iv) Executive shall have six (6) months following the expiration or termination of the Consulting Agreement to exercise
 the Options to the extent they have vested and become exercisable as of such date, provided that (A) any Option shall not be
 exercisable later than the original expiration date of such option, and (B) to the extent that any Option was intended to be an
 "incentive stock option", such option shall, as of the date hereof, be treated as a nonstatutory stock option for tax
 purposes; and (v) any such Options will cease vesting immediately upon expiration or termination of the Consulting Term for any
 reason in accordance with Section 2 of the Consulting Agreement.

4.  **<u>Release of Claims</u>** – In exchange for the consideration set forth in this Agreement,
which Executive acknowledges he would not otherwise be entitled to receive, Executive hereby fully, forever, irrevocably and unconditionally
releases, remises and discharges the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of
their respective past and present officers, directors, stockholders, partners, members, employees, agents, representatives, plan administrators,
attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the " <u>Released Parties</u> ")
from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts,
reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses
(including attorneys' fees and costs), of every kind and nature that Executive ever had or now has against any or all of the Released
Parties up to the date on which he signs this Agreement, whether known or unknown, including, but not limited to, any and all claims arising
out of or relating to Executive's employment with, separation from, and/or ownership of securities of the Company, including, but
not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e <u>et seq.</u>, the Americans With
Disabilities Act of 1990, 42 U.S.C. § 12101 <u>et seq.</u>, the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. §
2000ff <u>et seq.</u>, the Family and Medical Leave Act, 29 U.S.C. § 2601 <u>et seq.</u>, the Worker Adjustment and Retraining Notification
Act (" <u>WARN</u> "), 29 U.S.C. § 2101 <u>et seq.</u>, the Rehabilitation Act of 1973, 29 U.S.C. § 701 <u>et seq.</u>,
Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. § 1681 <u>et seq.</u>, and the Employee Retirement
Income Security Act of 1974 (" <u>ERISA</u> "), 29 U.S.C. § 1001 <u>et seq.</u>, all as amended; all claims arising out
of the Massachusetts Fair Employment Practices Act, Mass. Gen. Laws ch. 151B, § 1 <u>et seq.</u>, the Massachusetts Civil Rights
Act, Mass. Gen. Laws ch. 12, §§ 11H and 11I, the Massachusetts Equal Rights Act, Mass. Gen. Laws. ch. 93, § 102 and Mass.
Gen. Laws ch. 214, § 1C (Massachusetts right to be free from sexual harassment law), the Massachusetts Labor and Industries Act,
Mass. Gen. Laws ch. 149, § 1 <u>et seq.</u>, Mass. Gen. Laws ch. 214, § 1B (Massachusetts right of privacy law), the Massachusetts
Maternity Leave Act, Mass. Gen. Laws ch. 149, § 105D, and the Massachusetts Small Necessities Leave Act, Mass. Gen. Laws ch. 149,
 § 52D, all as amended; all rights and claims under the Massachusetts Wage Act, Mass. Gen. Laws ch. 149, § 148 <u>et seq.</u>,
as amended (Massachusetts law regarding payment of wages and overtime), including any rights or claims thereunder to unpaid wages, including
overtime, bonuses, commissions, and accrued, unused vacation time; all common law claims including, but not limited to, actions in defamation,
intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract (including, without
limitation, all claims arising out of or related to the Employment Agreement); all state and federal whistleblower claims to the maximum
extent permitted by law; and any claim or damage arising out of Executive's employment with and/or separation from the Company (including
a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above;
provided, however, that this release of claims shall not (i) prevent Executive from filing a charge with, cooperating with, or participating
in any investigation or proceeding before, the Equal Employment Opportunity Commission or a state fair employment practices agency (except
that Executive acknowledges that he may not recover any monetary benefits in connection with any such charge, investigation, or proceeding,
and Executive further waives any rights or claims to any payment, benefit, attorneys' fees or other remedial relief in connection
with any such charge, investigation or proceeding), (ii) deprive Executive of his rights with respect to the Severance Benefits,
or any vested rights under any employee benefit plan or policy, stock plan or deferred compensation arrangement, or any health care continuation
to the extent required by applicable law; or (iii) deprive Executive of any rights Executive may have to be indemnified by the Company
as provided in any agreement between the Company and Executive or pursuant to the Company's Certificate of Incorporation or by-laws.

5.  **<u>Ongoing Obligations</u>** – Executive acknowledges and reaffirms his obligation, except
as otherwise permitted by Section 9 below, both during the Transition Period and thereafter, to keep confidential and not to use
or disclose any and all non-public information concerning the Company acquired by his during the course of his employment with the Company,
including, but not limited to, any non-public information concerning the Company's business, operations, products, programs, affairs,
performance, personnel, technology, science, intellectual property, plans, strategies, approaches, prospects, financial condition or development
related matters. Executive also acknowledges all of his continuing obligations pursuant to the Restrictive Covenants Agreement, which
survive his separation from employment with the Company and shall remain in full force and effect.

6.  **<u>Non-Disparagement</u>** – Executive understands and agrees that, except as otherwise permitted by Section 9 below, he will not, during the Transition Period
or thereafter, in public or private, make any false, disparaging, negative, critical, adverse, derogatory or defamatory statements, whether
orally or in writing, including online (including, without limitation, on any social media, networking, or employer review site) or otherwise,
to any person or entity, including, but not limited to, any media outlet, industry group, key opinion leader, financial institution, research
analyst or current or former employee, board member, consultant, shareholder, client or customer of the Company, regarding the Company,
or any of the other Released Parties, or regarding the Company's business, operations, products, programs, affairs, performance,
personnel, technology, science, intellectual property, plans, strategies, approaches, prospects, financial condition or development related
matters. For the avoidance of doubt, the foregoing shall not prevent Executive from stating or repeating factual information with respect
to the Company or its assets which is otherwise publicly available. The Company agrees to instruct the members of its management team
not to, either during the Transition Period or thereafter, in public or private, make any false or defamatory statements, whether orally
or in writing, including online (including, without limitation, on any social media or networking site) or otherwise, to any person or
entity, including, but not limited to, any media outlet, industry group, key opinion leader, financial institution, research analyst or
current or former employee, board member, consultant, shareholder, client or customer of the Company, regarding Executive; provided, however,
that nothing herein shall be construed as requiring the Company to issue an instruction limiting or restricting such individuals from
engaging in discussions in the regular course of business about Executive's work during the Transition Period, or from disclosing
events or circumstances in such manner as they or the Company deem necessary to comply with or satisfy their or the Company's disclosure,
reporting or other obligations under applicable law.

7.  **<u>Return of Company Property</u>** –
Executive confirms that, no later than the Separation Date (or at such earlier time as requested by the Company), he will return
to the Company all keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software, printers,
flash drives and other storage devices, wireless handheld devices, cellular phones, tablets, etc.), Company identification, and any
other Company owned property in his possession or control, and that he will leave intact all, and will not otherwise destroy, delete,
or make inaccessible to the Company any, electronic Company documents, including, but not limited to, those that he developed or helped
to develop during his employment, and that he will not (a) retain any copies in any form or media; (b) maintain access to any
copies in any form, media, or location; (c) store any copies in any physical or electronic locations that are not readily accessible
or not known to the Company or that remain accessible to him; or (d) send, give, or make accessible any copies to any persons or
entities that the Company has not authorized to receive such electronic or hard copies. Executive further confirms that, no later than
the Separation Date (or at such earlier time as requested by the Company), he will cancel all accounts for his benefit, if any, in the
Company's name, including but not limited to, credit cards, telephone charge cards, cellular phone accounts, and computer accounts.

8.  **<u>Confidentiality</u>** – Executive understands and agrees that, except as otherwise permitted
by Section 9 below, the contents of the negotiations and discussions resulting in this Agreement shall be maintained as confidential
by Executive and his agents and representatives and shall not be disclosed except as otherwise agreed to in writing by the Company and
except to his immediate family, legal, financial and tax advisors, on the condition that any individuals so informed must hold the above
information in strict confidence.

9.  **<u>Scope of Disclosure Restrictions</u>** – Nothing in this Agreement or elsewhere prohibits
Executive from communicating with government agencies about possible violations of federal, state, or local laws or otherwise providing
information to government agencies, filing a complaint with government agencies, or participating in government agency investigations
or proceedings. Executive is not required to notify the Company of any such communications; provided, however, that nothing herein authorizes
the disclosure of information Executive obtained through a communication that was subject to the attorney-client privilege. Further, notwithstanding
Executive's confidentiality and nondisclosure obligations, Executive is hereby advised as follows pursuant to the Defend Trade Secrets
Act: "An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure
of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly,
or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made
in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. An individual who files a
lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the
individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the
trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order."

10.  **<u>Cooperation</u>** – Executive agrees that, to the extent permitted by law, he shall cooperate
fully with the Company in the investigation, defense or prosecution of any claims or actions which already have been brought, are currently
pending, or which may be brought in the future against the Company by a third party or by or on behalf of the Company against any third
party, whether before a state or federal court, any state or federal government agency, or a mediator or arbitrator. Executive's
full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with the Company's
counsel, at reasonable times and locations designated by the Company, to investigate or prepare the Company's claims or defenses,
to prepare for trial or discovery or an administrative hearing, mediation, arbitration or other proceeding, to provide any relevant information
in hers possession, and to act as a witness when requested by the Company. The Company will reimburse Executive for all reasonable and
documented out of pocket costs that he incurs to comply with this paragraph. Executive further agrees that, to the extent permitted by
law, he will notify the Company promptly in the event that he is served with a subpoena (other than a subpoena issued by a government
agency), or in the event that he is asked to provide a third party (other than a government agency) with information concerning any actual
or potential complaint or claim against the Company.

11.  **<u>Amendment and Waiver</u>** – This Agreement and the Additional Release, upon their
 respective effective dates, shall be binding upon the Parties and may not be modified in any manner, except by an instrument in
 writing of concurrent or subsequent date signed by duly authorized representatives of the Parties. This Agreement and the Additional
 Release are binding upon and shall inure to the benefit of the Parties and their respective agents, assigns, heirs,
 executors/administrators/personal representatives, and successors. (For the avoidance of doubt, if Executive dies during the
 Transition Period or during the Severance Payment Period, any Severance Benefits not yet paid or exhausted at the time of
 Executive's death shall, to the extent permitted by law, inure to the benefit of, and shall be paid or made available to,
 Executive's heirs, executors, administrators or personal representatives, with such amounts being paid at the same time and on
 the same schedule as set forth in Section 2 above.) No delay or omission by the Company in exercising any right under this Agreement
 or the Additional Release shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one
 occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other
 occasion.

12.  **<u>Validity</u>** – Should any provision of this Agreement or the Additional Release be declared
or be determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions
shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this Agreement or
the Additional Release.

13.  **<u>Nature of Agreement</u> –** Both Parties understand and agree that this Agreement is a separation
and release of claims agreement and does not constitute an admission of liability or wrongdoing on the part of the Company or Executive.

14.  **<u>Time for Consideration and Revocation; Acknowledgements</u> –** Executive acknowledges that
he was initially presented with this Agreement on February 17, 2023 (the " <u>Receipt Date</u> "), and that he has been
given a reasonable amount of time to consider this Agreement. Executive understands that this Agreement shall be of no force or effect
unless he signs and returns this Agreement at or before 10:00 p.m. Eastern time on February 22, 2023 (the date of such execution,
the " <u>Agreement Effective Date</u> "). Executive further understands that he will not be eligible to receive the Severance
Benefits unless he timely signs, returns, and does not revoke the Additional Release. Executive acknowledges that he has been given at
least twenty-one (21) days following the Receipt Date to consider the Additional Release (such 21-day period, the " <u>Consideration Period</u> "), and that the Company is hereby advising him to consult with an attorney of his own choosing prior to signing this
Agreement and the Additional Release. Executive further acknowledges and agrees that any changes made to this Agreement or any exhibits
or attachments hereto following his initial receipt of this Agreement on the Receipt Date, whether material or immaterial, shall not re-start
or affect in any manner the Consideration Period. Executive understands that he may revoke the Additional Release for a period of seven
(7) days after he signs it (the " <u>Revocation Period</u> ") by notifying the Company in writing, and that the Additional
Release shall not be effective or enforceable until the expiration of the Revocation Period (the day immediately following expiration
of the Revocation Period, the " <u>Additional Release Effective Date</u> "). Executive understands and agrees that by entering
into the Additional Release he will be waiving any and all rights or claims he may have under the Age Discrimination in Employment Act,
as amended by the Older Workers Benefit Protection Act, and that he will have received consideration beyond that to which he was previously
entitled.

15.  **<u>Voluntary Assent</u> –** Executive affirms that no other promises or agreements of any kind
have been made to or with Executive by any person or entity whatsoever to cause him to sign this Agreement, and that he fully understands
the meaning and intent of this Agreement and that he has had the opportunity to consult counsel of his own choosing. Executive further
states and represents that he has carefully read this Agreement, understands the contents herein, freely and voluntarily assents to all
of the terms and conditions hereof, and signs his name of his own free act.

16.  **<u>Governing Law</u>** – This Agreement shall be interpreted and construed by the laws of the
Commonwealth of Massachusetts, without regard to conflict of laws provisions. Each of the Company and Executive hereby irrevocably submits
to and acknowledges and recognizes the exclusive jurisdiction and venue of the courts of the Commonwealth of Massachusetts, or if appropriate,
the United States District Court for the District of Massachusetts (which courts, for purposes of this Agreement and the Additional Release,
are the only courts of competent jurisdiction), over any suit, action or other proceeding arising out of, under or in connection with
this Agreement or the subject matter thereof.

17.  **<u>Entire Agreement</u>** – This Agreement, including the Additional Release, the Restrictive
Covenants Agreement, and the Consulting Agreement, contains and constitutes the entire understanding and agreement between the Parties
hereto with respect to Executive's transition and separation from the Company, and the settlement of claims against the Company,
and cancels all previous oral and written negotiations, agreements, commitments and writings in connection therewith, including, without
limitation, the Employment Agreement.

18.  **<u>Counterparts</u>** – This Agreement may be executed in several counterparts, each of which
shall be deemed to be an original, but all of which together will constitute one and the same Agreement. Facsimile and PDF signatures
shall be deemed to be of equal force and effect as originals.

[*Remainder of page intentionally left blank*]

IN WITNESS WHEREOF, the Parties have set their hands and seals to this Agreement as of the date(s) written below.

---

| | | | |
|:---|:---|:---|:---|
| Voyager THERAPEUTIcs, INC. | Voyager THERAPEUTIcs, INC. |  |  |
| By: | /s/ Alfred Sandrock, M.D., Ph.D. | Date: | February 22, 2023 |
| Name: | Alfred Sandrock, M.D., Ph.D. |  |  |
| Title: | Chief Executive Officer |  |  |

---

*I hereby agree to the terms and conditions set forth above. I have been given a reasonable amount of time to consider this Agreement and I have chosen to execute this Agreement on the date below. I further understand that my receipt of consideration pursuant to the Agreement is contingent upon my timely execution, return, and non-revocation of the Additional Release, and that I have been given at least twenty-one (21) days to consider such Additional Release, and will have seven (7) days in which to revoke my acceptance after I sign such Additional Release.*

---

| | | |
|:---|:---|:---|
| Robert W. Hesslein | | |
| /s/ Robert W. Hesslein | Date: | February 22, 2023 |

---

[*Signature Page to Separation and Release of Claims Agreement*]